Patents by Inventor Yi-Ming Chiang

Yi-Ming Chiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150803
    Abstract: A non-human organism for upgrading intermediate oxidation products formed by catalytic degradation of alkanes or polystyrenes is provided. The non-human organism is genetically modified to convert the intermediate oxidation products to secondary metabolites, and in particular to include a positive feedback loop construction in the promotor system. A method includes steps of catalytically degrading alkanes or polystyrene in an oxidizing environment to form intermediate products with one or more catalysts and contacting the intermediate products with the non-human organism such that intermediate oxidation products are converted to secondary metabolites.
    Type: Application
    Filed: October 16, 2023
    Publication date: May 9, 2024
    Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA, UNIVERSITY OF KANSAS
    Inventors: Berl OAKLEY, Travis J. WILLIAMS, Yi-Ming CHIANG, Clay C. WANG, Yuhao CHEN, Swati BIJLANI, C. Elizabeth OAKLEY, Christian Anthony RABOT
  • Publication number: 20230242866
    Abstract: The present disclosure relates to transgenic fungal cells and methods of making the same such that the transgenic fungal cells include one or more exogenous biosynthetic gene clusters integrated into the host genome. The genes of the exogenous biosynthetic gene cluster may be operably linked to a transgenic region of an endogenous biosynthetic gene cluster that includes a native promoter to control expression of the exogenous genes.
    Type: Application
    Filed: December 13, 2022
    Publication date: August 3, 2023
    Inventors: Clay C. WANG, Yi-Ming CHIANG
  • Patent number: 10118945
    Abstract: Modified fungal strains having deleted gene clusters are provided. The modified fungal strains include A. nidulans. The deleted gene clusters are selected from the group of gene clusters responsible for the biosynthesis of sterigmatocystin, emericellamides, asperfuranone, monodictyphenone, terrequinone, F9775A, F9775B, asperthecin, and both portions of the split cluster that makes austinol and dehydroaustinol. Methods for making compounds by culturing the fungus in a growth media and separating the compound from the fungus and/or separating the compound from the growth media are included, as are the compounds and compositions comprising them.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 6, 2018
    Assignees: University of Kansas, University of Southern California
    Inventors: Berl Oakley, Manmeet Ahuja, Ruth Entwistle, Christine Oakley, Yi-Ming Chiang, Clay Wang
  • Publication number: 20170121719
    Abstract: Modified fungal strains having deleted gene clusters are provided. The modified fungal strains include A. nidulans. The deleted gene clusters are selected from the group of gene clusters responsible for the biosynthesis of sterigmatocystin, emericellamides, asperfuranone, monodictyphenone, terrequinone, F9775A, F9775B, asperthecin, and both portions of the split cluster that makes austinol and dehydroaustinol. Methods for making compounds by culturing the fungus in a growth media and separating the compound from the fungus and/or separating the compound from the growth media are included, as are the compounds and compositions comprising them.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 4, 2017
    Inventors: Berl Oakley, Manmeet Ahuja, Ruth Entwistle, Christine Oakley, Yi-Ming Chiang, Clay Wang
  • Patent number: 8048860
    Abstract: A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: November 1, 2011
    Assignee: Academia Sinica
    Inventors: Wen-Chin Yang, Shu-Lin Chang, Lee-Tian Chang, Yi-Ming Chiang, Lie-Fen Shyur
  • Patent number: 7999004
    Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: August 16, 2011
    Assignee: National Taiwan University
    Inventors: Ching-jing Huang, Wei-Yi Cheng, Yueh-Hsiung Kuo, Yi-Ming Chiang
  • Patent number: 7691575
    Abstract: Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN ? or IL-2 transcription.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: April 6, 2010
    Assignee: Academia Sinica
    Inventors: Wen-Chin Yang, Shu-Lin Chang, Yi-Ming Chiang, Lie-Fen Shyur
  • Publication number: 20090062216
    Abstract: A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 3, 2008
    Publication date: March 5, 2009
    Applicant: Academia Sinica
    Inventors: Wen-Chin Yang, Shu-Lin Chang, Lee-Tian Chang, Yi-Ming Chiang, Lie-Fen Shyur
  • Publication number: 20080193432
    Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.
    Type: Application
    Filed: February 9, 2007
    Publication date: August 14, 2008
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Ching-jang Huang, Wei-Yi Cheng, Yueh-Hsiung Kuo, Yi-Ming Chiang
  • Publication number: 20070053998
    Abstract: A compound of the formula: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; and p is 1, 2, 3, or 4. Also disclosed is use of the compound to inhibit Th1 differentiation, promote Th2 differentiation, and treat certain disorders.
    Type: Application
    Filed: September 2, 2005
    Publication date: March 8, 2007
    Inventors: Wen-Chin Yang, Shu-Lin Chang, Lee-Tian Chang, Yi-Ming Chiang, Lie-Fen Shyur
  • Publication number: 20070048394
    Abstract: Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN ? or IL-2 transcription.
    Type: Application
    Filed: August 29, 2005
    Publication date: March 1, 2007
    Inventors: Wen-Chin Yang, Shu-Lin Chang, Yi-Ming Chiang, Lie-Fen Shyur